RheumaLogics ApS: Financial statements 2025
CVR: 45253295
Source: annual report 2025, Danish Business Authority
05/12/2024 – 31/12/2025
RheumaLogics ApS (CVR 45253295) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -44,590,096 and a net result of DKK -39,672,013. Equity in the 2025 report amounted to DKK 22,357,721. The solvency ratio was 31.4%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -44,590,096
- Profit/Loss
- DKK -39,672,013
- Equity
- DKK 22,357,721
- Total Assets
- DKK 71,236,326
- Employees
- 1
Official annual report
How creditworthy is RheumaLogics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout RheumaLogics ApS
RheumaLogics ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Søren Sylvester Skjærbæk. The board consists of Jørgen Søberg Petersen (chair), Alex Thomas Pasteur, Balaji Muralidhar and Gabor Gyulveszi. The company's owners include Novo Holdings A/S, Demetrios Thomas Braddock and F-Prime Capital Partners Life Sciences Fund IX LP. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -44,590,096 and a net result of DKK -39,672,013. Equity in the 2025 report amounted to DKK 22,357,721.